Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP NASDAQ:CARA TSE:TEV NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsTLRYTilray Brands$1.19+3.5%$0.85$0.35▼$1.88$1.27B2.0396.02 million shs40.90 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%0.00%+37.64%TEVTervita0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands+3.48%-13.77%+92.81%+193.39%-28.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsTLRYTilray Brands$1.19+3.5%$0.85$0.35▼$1.88$1.27B2.0396.02 million shs40.90 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%0.00%+37.64%TEVTervita0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands+3.48%-13.77%+92.81%+193.39%-28.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ACARACara Therapeutics 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ATLRYTilray Brands 2.33Hold$1.9462.82% UpsideCurrent Analyst Ratings BreakdownLatest TEV, AUP, TLRY, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00TLRYTilray Brands$821.31M1.59$0.15 per share7.96$1.40 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ATEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest TEV, AUP, TLRY, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02CARACara TherapeuticsN/A4.774.71TEVTervita440.441.000.86TLRYTilray Brands0.202.461.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ACARACara Therapeutics44.66%TEVTervitaN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ACARACara Therapeutics3.10%TEVTervitaN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableCARACara Therapeutics804.57 million4.43 millionOptionableTEVTervita36,800115.66 millionN/ANot OptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableTEV, AUP, TLRY, and CARA HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Trading Up 2.2% - Here's What Happened1 hour ago | marketbeat.comCannabis Stocks To Add to Your Watchlist - September 5th4 hours ago | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Down 4.2% - Should You Sell?September 5 at 8:14 PM | marketbeat.comTop Cannabis Stocks To Follow Now - September 4thSeptember 5 at 2:11 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 5.2% - Here's WhySeptember 4 at 2:56 PM | marketbeat.comBreckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey WhiskeySeptember 4 at 7:00 AM | globenewswire.comTilray Brands (TLRY) Surges on Cannabis Sector Buzz as Profits Go Up in SmokeSeptember 3 at 10:20 PM | msn.comTilray Brands (NASDAQ:TLRY) Stock Price Down 9.1% - Should You Sell?September 3 at 2:45 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - What's Next?September 3 at 1:23 PM | marketbeat.com3 Top Canadian Marijuana Stock Choices For A Possible Breakout In 2025September 3 at 9:58 AM | marijuanastocks.comMShock Top and Auntie Anne's® Make It Official - Beer Kneads PretzelsSeptember 3 at 7:30 AM | globenewswire.comBreckenridge Distillery Expands California Distribution with WinebowSeptember 3 at 7:00 AM | globenewswire.comInvesco Ltd. Has $1.10 Million Stake in Tilray Brands, Inc. $TLRYSeptember 3 at 3:07 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 5.8% - Time to Sell?August 30, 2025 | marketbeat.comWhy Tilray (TLRY) Shares Are Trading Lower TodayAugust 29, 2025 | finance.yahoo.comTop Cannabis Stocks To Watch Now - August 28thAugust 29, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Up 3.3% - Still a Buy?August 29, 2025 | marketbeat.comPot Stocks Plunge After Rally: Is Betting on Rescheduling Worth the Risk?August 29, 2025 | 247wallst.comTilray Brands (TLRY)’s Breckenridge Distillery Launches Mountain ShotAugust 29, 2025 | finance.yahoo.comTilray Brands (NASDAQ:TLRY) Shares Down 5.9% - Should You Sell?August 28, 2025 | marketbeat.comJefferies Raises Tilray (TLRY) Price Target on Potential Cannabis ReschedulingAugust 28, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025TEV, AUP, TLRY, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.Tilray Brands NASDAQ:TLRY$1.19 +0.04 (+3.48%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.16 -0.03 (-2.94%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
